FDA approves Baxter's HyQvia for primary immunodeficiency

FDA approved HyQvia from Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics Inc. (NASDAQ:HALO) to treat adults with primary immunodeficiency (PI).

HyQvia is a subcutaneous formulation of Gammagard, an IgG antibodies plasma-based therapy from Baxter, and recombinant human PH20 hyaluronidase ( rHuPH20) from Halozyme. The two companies partnered in 2007. ...